BridgeBio Pharma, Inc. · NASDAQ:BBIO
Kumar Neil sold 54,980 BridgeBio Pharma, Inc. shares (Form 4)
Traded Nov 18 to Nov 19, 2026 · Filed Nov 20, 2026
From Nov 18 to Nov 19, 2026, Kumar Neil (Director, Chief Executive Officer) sold 54,980 BridgeBio Pharma, Inc. shares at an average US$77.86 for US$4.28M under a trading plan, leaving 475,686 shares. Filed Nov 20, 2026 (Form 4).
- Sold
- 54,980 shares
- Price
- US$77.86 average (US$76.99 to US$79.29)
- Value
- US$4.28M
- Holding after
- 475,686 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chief Executive Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Common Stock | Sale | 4,490 | US$76.99 | 273,817 | Direct |
| Nov 18, 2026 | Common Stock | Sale | 30,490 | US$77.83 | 243,327 | Direct |
| Nov 18, 2026 | Common Stock | Sale | 1,277 | US$76.99 | 494,409 | Indirect |
| Nov 18, 2026 | Common Stock | Sale | 8,723 | US$77.83 | 485,686 | Indirect |
| Nov 19, 2026 | Common Stock | Sale | 8,500 | US$78.35 | 477,186 | Indirect |
| Nov 19, 2026 | Common Stock | Sale | 1,500 | US$79.29 | 475,686 | Indirect |
Source
Download original · View original at SEC
Related
- BridgeBio Pharma, Inc.
- Kumar Neil
- BridgeBio Pharma, Inc. shareholders
- Form 4 · Kumar Neil · Nov 18, 2026
- Form 4 · Kumar Neil · Sep 21, 2026
- Form 4 · Kumar Neil · Aug 20, 2026
- Form 4 · Kumar Neil · Aug 18, 2026
- Form 4 · Kumar Neil · Jun 8, 2026
- Form 4 · Apuli Maricel · Nov 18, 2026
- Form 4 · Trimarchi Thomas · Nov 18, 2026
- Schedule 13G/A · Farallon Capital Management, L.L.C. · Nov 12, 2026
- Form 4 · Apuli Maricel · Nov 3, 2026
- Schedule 13G · BlackRock, Inc. · Oct 27, 2026